Targeting a key protein to block COVID-19 and respiratory viruses
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung
This study is testing a new treatment that aims to stop COVID-19 and other respiratory viruses from getting into lung cells by blocking a specific protein, and it's designed for people who want to help improve outcomes for those affected by these viruses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10913504 on NIH RePORTER |
What this research studies
This research focuses on developing a new antiviral treatment aimed at preventing COVID-19 and other respiratory viruses from entering lung cells. The approach involves targeting a specific protein called TMPRSS2, which the virus uses to gain access to cells in the lungs. By inhibiting this protein, the researchers hope to stop the virus from infecting lung cells, potentially leading to better outcomes for patients suffering from COVID-19. The study will utilize advanced techniques to test the effectiveness of this treatment in laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for severe COVID-19, such as those with underlying health conditions or those who are unvaccinated.
Not a fit: Patients who have already recovered from COVID-19 and have developed immunity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new antiviral therapy that significantly reduces the severity and spread of COVID-19.
How similar studies have performed: Other research has shown promise in targeting viral entry mechanisms, indicating that this approach could be effective.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Chen, Ya-Wen — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chen, Ya-Wen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.